INTRODUCTION Over the last decade or so, no other subspecialty of medicine has seen such technological innovations, as interventional cardiology. These advances have revolutionized the management of coronary artery disease. From statin drugs to oral platelets inhibitors like clopidogrel and ticlopidine, intravenous platelet glycoprotein IIb/IIIa receptor blockers like Abciximab (Reo-Pro), Eptif...

We assessed the efficacy and safety of tirofiban intracoronary versus intravenous administration during percutaneous coronary intervention for patients with acute coronary syndrome. The databases of PubMed, Web of Science, China National Knowledge Infrastructure, and WanFang Database were retrieved. A total of 437 articles were found, according to inclusive and exclusive criteria, 13 of which w...

The role of GP IIb/IIIa antagonists has been focused on patients with acute coronary syndromes undergoing PCI. In the ISAR-REACT 2 study abciximab given in patients with NSTEACS undergoing PCI already treated with 600 mg clopidogrel improved 30-day death and reinfarction rate in troponin positive patients. In the large EARLY-ACS trial upstream therapy with eptifibatide in high risk with NSTE-AC...

antiplatelet treatment Offer a single loading dose of 300 mg aspirin as soon as possible and continue indefinitely unless contraindicated by bleeding risk or aspirin hypersensitivity. [Based on a high quality systematic review and cost effectiveness evidence] Offer a loading dose of 300 mg clopidogrel in addition to aspirin to patients with a predicted six month mortality of more than 1.5%, or ...

BACKGROUND AND PURPOSE The goal of stent retriever-based thrombectomy is removal of embolic clots in patients with intracranial large artery occlusion. However, outcomes of stent retrieval may differ between acute arterial occlusions due to intracranial atherosclerotic disease (IAD) and those due to embolism. This case series describes the outcomes of stent retriever-based thrombectomy and resc...

BACKGROUND The primary mechanism of action of glycoprotein (GP) IIb/IIIa antagonists is inhibition of the final common pathway of platelet aggregation: fibrinogen binding to the GP IIb/IIIa complex. However, it has been reported that induction of fibrinogen binding and platelet aggregation is an intrinsic prothrombotic property of low-dose GP IIb/IIIa antagonists. These apparently paradoxical r...